Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
Prelude Therapeutics, a clinical-stage precision oncology company, announced the pricing of an underwritten offering of approximately 18 million shares of common stock and pre-funded warrants to raise gross proceeds of about $90 million. The offering, led by RA Capital Management and participated by other healthcare-focused investors, is expected t…